iShares Neuroscience and Healthcare ETF (IBRN) Holdings
이 페이지는 영어 원문에서 AI로 기계 번역되었습니다. 영어 버전이 기준입니다. 영어 버전 읽기
정보 제공만을 목적으로 합니다. 재정적 조언이 아닙니다.
iShares Neuroscience and Healthcare ETF (IBRN) has a last stored price of $31.40, as of the Oct 26, 2026 trading session. It has a 0.47% expense ratio and $5M in assets under management.
Holdings and weights below are as of Mar 15, 2026. In the stored portfolio snapshot, the largest listed holding is Praxis Precision Medicines Inc Ordinary Shares (PRAX) at 5.61%, and the largest sector allocation is Healthcare at 100.0%.
iShares Neuroscience and Healthcare ETF (IBRN) ETF — Price, Holdings & Analysis
ETF 개요
위험 지표
- 베타: 1.20
운용보수율
IBRN은(는) 무엇을 보유하고 있나요?
이 펀드 데이터는 45일 이상 지났습니다. 최신 보유 종목은 발행사에서 확인하세요.
펀드는 어떻게 배분되어 있나요?
| 섹터 | 비중 |
|---|---|
| 헬스케어 | 100.0% |
| 국가 | 비중 |
|---|---|
| 미국 | 68.9% |
| 캐나다 | 5.7% |
| 아일랜드 | 4.5% |
| 영국 | 3.4% |
| 네덜란드 | 3.4% |
| 스웨덴 | 2.9% |
| 대한민국 | 2.5% |
| 덴마크 | 2.1% |
| 중국 | 1.8% |
| 일본 | 1.7% |
배당수익률
- iShares Morningstar Small-Cap Growth ETF (JKK) — 0.06% expense ratio
- ARK Innovation ETF (ARKK) — 0.75% expense ratio
- Invesco QQQ Trust, Series 1 (QQQ) — 0.18% expense ratio
- State Street Energy Select Sector SPDR ETF (XLE) — 0.08% expense ratio
- WisdomTree Emerging Markets ESG Fund (DVEM) — 0.32% expense ratio
- Goldman Sachs ActiveBeta Emerging Markets Equity ETF (GEM) — 0.59% expense ratio
- State Street SPDR Dow Jones Industrial Average ETF Trust (DIA) — 0.16% expense ratio
- State Street Technology Select Sector SPDR ETF (XLK) — 0.08% expense ratio
- iShares iBoxx $ High Yield Corporate Bond ETF (HYG) (Fixed Income) — 0.49% expense ratio
- iShares 20+ Year Treasury Bond ETF (TLT) (Fixed Income) — 0.15% expense ratio
- iShares MSCI UAE ETF (UAE) (Equity) — 0.59% expense ratio
- iShares Climate Conscious & Transition MSCI USA ETF (USCL) (Equity) — 0.08% expense ratio
- iShares Securitized Income Active ETF (SECU) (Fixed Income) — 0.40% expense ratio
질문 및 답변
What is IBRN and what does it track?
The iShares Neuroscience and Healthcare ETF (IBRN) seeks to track the investment results of an index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience.
This means the fund invests in companies involved in the research, development, and commercialization of treatments and technologies related to neurological disorders and brain health.
What is the expense ratio for IBRN?
The expense ratio for IBRN is 0.47%. This means that for every $10,000 invested in the fund, $47 is used to cover the fund's operating expenses annually.
While this is a cost to consider, it's important to weigh it against the potential benefits of the fund's targeted investment strategy. When compared to the average expense ratio for equity ETFs, IBRN's expense ratio is slightly higher.
What are the top holdings in IBRN?
The top holdings in IBRN, as of 2026-03-15, include Praxis Precision Medicines Inc (5.61%), Axsome Therapeutics Inc (4.53%), and Biogen Inc (4.36%). Alkermes PLC (4.21%) and Supernus Pharmaceuticals Inc (4.07%) also rank among the fund's largest allocations.
These companies represent a significant portion of IBRN's portfolio and reflect the fund's focus on neuroscience and healthcare innovation. These holdings are primarily in the pharmaceutical and biotechnology industries.
Is IBRN a good long-term investment?
Determining whether IBRN is a suitable long-term investment depends on an individual's investment goals, risk tolerance, and time horizon. IBRN offers targeted exposure to the neuroscience and healthcare sector, which may present growth opportunities but also involves specific risks.
The fund's beta of 1.20 suggests higher volatility compared to the broader market.
How does IBRN compare to similar ETFs?
IBRN differentiates itself through its specific focus on neuroscience and healthcare innovation. While other healthcare ETFs may offer broader exposure to the healthcare sector, IBRN targets companies directly involved in neuroscience-related activities.
The fund's expense ratio of 0.47% is comparable to other specialized ETFs.
Does IBRN pay dividends?
As of 2026-03-15, IBRN has a dividend yield of 0.00%. This indicates that the fund does not currently distribute dividends to its shareholders. Investors seeking income-generating investments may want to consider other ETFs with a higher dividend yield.
The fund's focus is primarily on capital appreciation through investments in growth-oriented companies within the neuroscience and healthcare sector.
면책 조항: 이 콘텐츠는 정보 제공만을 목적으로 하며 투자 조언을 구성하지 않습니다. 항상 자체 조사를 수행하고 재정 고문과 상담하십시오.
데이터는 정보 제공만을 목적으로 제공됩니다.
이 페이지는 기계가 작성했으며, 페이지별 사람 검수는 거치지 않았습니다. 편집 관리는 체계 차원에서 이루어집니다: 규칙과 출처를 점검하며, 개별 페이지는 점검하지 않습니다.